Has osteoporosis treatment failed when a fracture occurs?
August 31, 2012 in Diseases, Conditions, Syndromes
The International Osteoporosis Foundation (IOF) has published practical guidelines to assist clinicians in assessing treatment efficacy in patients who experience a fracture while on medication for osteoporosis.
Osteoporosis drug therapy typically reduces the risk of fracture in the range of 30-70% for vertebral fractures, 40-50% for hip fractures and 15-20% for non-vertebral fractures. Nevertheless, even an effective therapy does not completely eliminate the risk of fracture, and some patients will experience a fracture while complying with their prescribed treatment.
This situation is not just worrying for the patient, it also poses a challenge for the physician who must decide whether to continue or discontinue with the treatment regimen. Does the fracture signify that the patient has failed to respond to the particular treatment? Should the type of treatment be changed? Or is the patient one of a significant minority who fails to respond to available treatments, for a number of many possible reasons?
The IOF Inadequate Responders Working Group, comprised of international experts on IOF's Committee of Scientific Advisors, outlines many of the issues associated with clinical decisions in the treatment of osteoporosis. Professor Adolfo Diez-Perez, chair of the Working Group, explains, "Treatment issues are extremely complex. In addition there is a scarcity of data about the effectiveness of alternative treatments when one has been deemed to have failed. Notwithstanding these complexities and limitations, the Working Group has used the best available evidence to create a check list of pragmatic criteria which can help doctors define treatment failure and take appropriate action."
The position paper, published in the journal 'Osteoporosis International', outlines how the response to treatment in patients who have been complying with their treatment for at least six months can be assessed on the basis of the number of fractures, changes in bone mineral density and bone turnover markers.
Professor Cyrus Cooper, chair of the IOF Committee of Scientific Advisers, stated: "Recent advances in the management of osteoporosis have led to large numbers of patients being treated with a variety of drugs. An increasingly frequent clinical conundrum is the management of a patient who sustains a fracture while on treatment. Although patient and physician may view this as a sign of treatment failure, this is not always the case. The objective of the current practical guidance was to provide a clinical pathway whereby physicians can ascertain whether a patient has failed to respond adequately to an anti-osteoporosis treatment. As a result, doctors will be able to define treatment failure more effectively, and take appropriate action. The algorithm produced pays testimony to the expert input from a host of international scientific advisers, coming together to address this important clinical topic in a timely and efficient manner."
More information: Treatment failure in osteoporosis A. Diez-Perez, J. D. Adachi, D. Agnusdei, J. P. Bilezikian, J. E. Compston, S. R. Cummings, R. Eastell, E. F. Eriksen, J. Gonzalez-Macias and U. A. Liberman, et al. Osteoporosis International 2012, DOI: 10.1007/s00198-012-2093-8
Journal reference:
Osteoporosis International
Provided by
International Osteoporosis Foundation
-
Make or break time for osteoporosis treatment
Mar 10, 2008 |
not rated yet |
0
-
IOF urges systematic osteoporosis management after vertebral fracture augmentation
Aug 01, 2011 |
not rated yet |
0
-
Standardized protocols would greatly enhance clinical and research potential of BTMs
Dec 27, 2010 |
not rated yet |
0
-
New review outlines screening strategies for osteoporosis in young adults
Jun 19, 2012 |
not rated yet |
0
-
IOF and ECTS issue guidance on management of glucocorticoid-induced osteoporosis
Mar 27, 2012 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011
- More from Physics Forums - Independent Research
More news stories
FDA warns of infections tied to Tennessee pharmacy
(AP)—Government health officials are investigating several health problems reported with potentially contaminated medications made by a Tennessee specialty pharmacy.
Diseases, Conditions, Syndromes
May 24, 2013 |
not rated yet |
0
Comorbidities common with alopecia areata
(HealthDay)—Comorbid conditions often accompany alopecia areata, according to a study published online May 22 in JAMA Dermatology.
Diseases, Conditions, Syndromes
May 24, 2013 |
not rated yet |
0
Top-ranked golfer beats scoliosis
(HealthDay)—As a world-class golfer, Stacy Lewis' accomplishments are remarkable. But it was a physical challenge in her childhood that defined her ascent to the top of her sport.
Diseases, Conditions, Syndromes
May 24, 2013 |
not rated yet |
0
Saudi to send animal samples to US in coronavirus probe (Update)
Saudi Arabia said Friday it would send samples taken from animals possibly infected with a deadly SARS-like virus to the United States for testing in a bid to find the source of disease.
Diseases, Conditions, Syndromes
May 24, 2013 |
not rated yet |
0
WHO voices deep concern over spread of SARS-like virus
The World Health Organization voiced deep concern Thursday over the SARS-like virus that has killed 22 people in less than a year, saying it might potentially spread more widely between humans.
Diseases, Conditions, Syndromes
May 24, 2013 |
5 / 5 (1) |
0
First drug to improve heart failure mortality in over a decade
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...
Seniors more likely to crash when driving with pet, study finds
(HealthDay)—Animals make great companions for senior citizens, but elderly people who always drive with a pet in the car are far more likely to crash than those who never drive with a pet, researchers have ...
Heart failure accelerates male 'menopause'
Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...
Death highest in heart failure patients admitted in January, on Friday, and overnight
Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...
Feds fight morning-after pill age ruling in NY
(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...
New immune system discovered
(Medical Xpress)—A research team, led by Jeremy Barr, a biology post-doctoral fellow, unveils a new immune system that protects humans and animals from infection.
Sep 10, 2012
Rank: not rated yet